Start / Method
“The SpectraCure IDOSE® system is an exciting new approach for estimating the extent of necrosis during PDT, based on real time measurements of light distribution and photobleaching in the area under treatment”
Stephen G Bown, MD (Cambridge), AM (Harvard), DSc (Hon Lucknow), FRCP Emeritus Prof of Laser Medicine & Surgery, Division of Surgery & Interventional Science
Photodynamic therapy (PDT) is a treatment that makes the tissue light sensitive using a drug. The drug is activated with light by delivering a controlled amount of energy at a defined wavelength. This reaction causes the cancer cells to die. PDT is a well-established treatment method, for example, for treating certain types of skin tumors.
is PDT applied to tumors inside the body. Interstitial PDT, like traditional PDT, destroys cancer cells by using a drug that makes the tissue photosensitive and then delivering light to the tumor. The light is delivered through optical fibers, placed directly into the tumor.
The amount of light applied is continuously adjusted
A series of measurements is performed during the treatment to ensure that the correct light dose is delivered. This ensures that the cancer cells are eliminated, without damaging healthy surrounding tissue. The solution of using the same optical fibers for measurement as for treatment makes SpectraCure unique. This allows the IDOSE® software to calculate and control the light dose continuously throughout the treatment to achieve maximum treatment effect.
SpectraCure’s treatment method, interstitial PDT, is performed with our product consisting of:
Our PDT system with IDOSE® software is a completely new medical device for treatment, planning, and dose delivery of light. Treatment is focused and adapted to each patient’s tumor. SpectraCure has chosen recurrent prostate cancer as the first indication.
Patents
The Q-PRO® treatment system with IDOSE® is covered by several patents. The patent portfolio consists of 12 patents in 8 patent families. The basic patents relating to the operation of our laser system are approved in Europe, the USA, China, and,Japan, among other countries.
A new patent regarding our IDOSE® technology is approved by the US Patent Office,and the European Patent Office and is under examination in several other countries. The patent application relates to a technique for measuring the impact of bleeding and compensating for it.
Another new patent relating to improvements in the technical solution of the new generation of treatment systems has been approved in Europe. Outside of Europe, the same patent application is in PCT phase, i.e. international examination. The patent describes a technical solution for using the same optical fibers for measurement and treatment. Measurements from the optical fibers individualizes the treatment. This technology makes SpectraCure unique.
In addition, we have patented a wide range of methods for performing dose conversion during treatment.
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.
We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.